T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches
| Autor: | Sachin Gupta, Katherine Garcia de de Jesus, Kidist Tarekegn, Ana Colon Ramos, Amandeep S. Aujla |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty jak-stat t-cell prolymphocytic leukemia 030204 cardiovascular system & hematology bcl2 mtcp1 03 medical and health sciences 0302 clinical medicine In vivo Internal medicine medicine Genetics alemtuzumab Neoplasm Prolymphocytic leukemia business.industry General Engineering Hematology Cell cycle medicine.disease cytogenetic profile Clinical trial relapsed refractory tcl1 hdac inhibitor T-cell prolymphocytic leukemia Alemtuzumab business 030217 neurology & neurosurgery Ex vivo medicine.drug |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| Popis: | T-cell prolymphocytic leukemia (T-PLL) is a rare mature T-cell hematologic neoplasm with a very poor prognosis and limited treatment options to date. Single-agent alemtuzumab remains the first line of therapy for the treatment-naive and relapsed/refractory patients. Prospective clinical trials are difficult to conduct given that these patients have a short life expectancy after the initial diagnosis. As a result, researchers are implementing the use of targeted therapies in vitro and ex vivo followed by in vivo trials on a small subset of patients which are reviewed here. Newer approaches in the treatment of T-PLL are developing based on recognizing the cytogenetic phenotype of each patient and targeting the identified defective genes that are usually involved in the cell cycle regulation such as protooncogenes, tumor suppressors, and deoxyribonucleic acid (DNA) repair genes. These could potentially redirect the management in the near future and improve the overall survival (OS) and the progression-free survival (PFS) for these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|